AKT1 and cancer: mTORC2 can either compensate directly for the suppression of mTORC1 [26], or it can trigger other downstream responses independently of the PI3K-Akt-mTORC1 pathway [40], and these independent responses are now increasingly being recognized as important in cancer metabolic reprogramming [41].